AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02950454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous moderate exercise
Description: 20 min at 60-70% heart rate max on cycle ergometer
Study NCT03231033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
Study NCT03992820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS machine
Description: The trial group will have the TENS to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration.
Study NCT03992820 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: EMLA cream
Description: The control group will have EMLA applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution (this is already a procedure practised by many of the surgeons).~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration.
Study NCT00837304 — intervention group
Intervention type: DEVICE
Intervention: PillCam Colon Capsule
Description: PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
Study NCT00837304 — intervention group
Intervention type: PROCEDURE
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
Study NCT01961323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP\<140 and DBP \<90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
Study NCT03791476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhC1INH
Description: C1 esterase inhibitor
Study NCT03791476 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: saline solution
Study NCT04123054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile App
Description: Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator.
Study NCT04123054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile App + Basal-Bolus Optimization Algorithm
Description: Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator. In addition, participants will receive weekly app notifications with personalized recommendations for insulin parameter adjustments made by the optimization algorithm.
Study NCT03234751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continous IV infusion of Nesiritide
Description: Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
Study NCT03234751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic euglycemic clamp
Description: 48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
Study NCT03234751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 48 hours of placebo.
Study NCT02839915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Liquid levo-leucovorin via oral route. L-leucovorin is the active isomer.
Study NCT02839915 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo comparator
Study NCT01631877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin with acenocoumarol
Description: enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
Study NCT01631877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: injection placebo will be given for 5 days along with placebo tablets
Study NCT02746874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation (RFA)
Description: The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
Study NCT02746874 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simulated Radiofrequency Ablation (RFA)
Description: The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
Study NCT02106884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02106884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT00765544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anklebot
Description: The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
Study NCT00765544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
Study NCT04017104 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FDG PET/CT
Description: For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.
Study NCT04017104 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-DOTATOC PET/CT
Description: Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
Study NCT04017104 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-DCFPyL PET/CT
Description: Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
Study NCT03498365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCDA
Description: Experimental decision support
Study NCT03498365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delphi
Description: Standard support
Study NCT04139187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training with power and strength exercises
Description: The training will be compose by power and strength exercises and divided in two days. One day with the exercises: vertical jumps, box jumps, sit-ups, back-extension and guided squat. The second with half squat jumps, high straight jumps, bounding jumps, drop jumps and sprint. Both days will be started with warm up on treadmill running lasting 5 minutes at 6.5-7.5 km/h.~The training protocol includes 20 sessions with 2 sessions per week during 10 weeks (2 weeks to adaptation and others 8 to training with progression of load after 4 weeks).
Study NCT03388060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided SWL
Description: Ultrasound guided SWL for radiolucent renal stone
Study NCT03388060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dissolution therapy
Description: Alkalinization dissolution therapy for radiolucent renal stone
Study NCT03388060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined ultrasound guided SWL and dissolution therapy
Description: Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone
Study NCT02402543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study NCT02402543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
Study NCT02402543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT02402543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
Study NCT02402543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02921698 — intervention group
Intervention type: DEVICE
Intervention: FRED®
Description: Flow Re-Direction Endoluminal Device
Study NCT03144388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Variable Stepping Training
Description: Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
Study NCT03144388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Variable Non-specific Training
Description: Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
Study NCT01518777 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Half-dose isotope for NuclearStressTest
Description: Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
Study NCT00473642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: intravitreal administered ranibizumab 0.5 mg in 0.05 mL
Study NCT00473642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal administered ranibizumab 0.5 mg in 0.05 mL
Study NCT00473642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
Study NCT00473642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
Study NCT00982592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00982592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00982592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00982592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given PO
Study NCT00982592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Given PO
Study NCT00982592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01496339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenSCs transplantation
Description: 1×10\^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
Study NCT01496339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exogenous indulin injection daily
Description: traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
Study NCT01217866 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic assisted vaginal hysterectomy
Description: Surgical removal of uterus vaginally
Study NCT04129099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC022F
Description: GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.
Study NCT00089791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered by subcutaneous injection
Study NCT00089791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection
Study NCT02879942 — intervention group
Intervention type: OTHER
Intervention: Ultrasound study of the placenta
Description: The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.
Study NCT02879942 — intervention group
Intervention type: OTHER
Intervention: Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test
Study NCT03186079 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Toilet training
Description: Toilet training has been considered a routine method in treatment of constipation
Study NCT00645229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
Study NCT01732133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexfin
Study NCT04729699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and exercise for TMJ
Description: Aerobic exercise
Study NCT04729699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise at home
Description: Aerobic exercise
Study NCT01430598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Repair and Subacromial Decompression
Description: Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
Study NCT01430598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
Study NCT01024946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
Study NCT03822286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-training course
Description: Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
Study NCT03822286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support group
Description: A counseling master mix 8\~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40\~60 minutes each time.
Study NCT03822286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional classroom teaching course programs
Description: Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
Study NCT03273868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High velocity low amplitude manipulation
Description: The researcher manually applies a preload force on the T5/T6 level followed by a single posterior to anterior thrust.
Study NCT03273868 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
Study NCT02510976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Study NCT02510976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00853112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: tablet form, 1 mg, single dose (Day 1)
Study NCT00853112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: tablet form, 2 mg, single dose (Day 1)
Study NCT00853112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: tablet form, 4 mg, single dose (Day 1)
Study NCT00853112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: tablet form, 10 mg, single dose (Day 1)
Study NCT00853112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: tablet form, 20 mg, single dose (Day 1)
Study NCT00853112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet form, single dose (Day 1)
Study NCT00853112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: tablet form, 20 mg, single dose (Day 1)
Study NCT00429117 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: Internet survey lasting 30 to 40 minutes.
Study NCT00856362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Study NCT00856362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT04547660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Fresh frozen plasma collected by apheresis from recovered COVID-19 patients added to best supportive care.
Study NCT04547660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
Study NCT04547660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.